As Media Companies Struggle to Make Regional Sports Networks Successful, Can Sports Retailers Fare Any Better?

 

Key Points:

  • Regional Sports Networks lose subscribers after media giants like Dish Network remove AT&T’s SportsNet and Root Sports Channels from its channel list.
  • Consumers are moving en masse towards streaming services to watch television.
  • Because of prolonged delays to season openers, consumers turned to other resources besides sports for entertainment during the pandemic.

Commentary:

A recent report reveals that Fanatics, the sports retailer and trading card company, is looking to join the market for Regional Sports Networks. RSNs are currently key channels for broadcasting NBA, MLB and NHL games for localized viewers, but with more people cutting the cord, and companies disinvesting in their Regional Sports Network offerings, the future of these broadcast channels could be in jeopardy. MarketScale asked Trae Smith, former UCLA football player and Relationship Manager for Informa’s Wealth Management team, what this potential acquisition could mean for the industry and why Fanatics sees gold in this investment.

Abridged Thoughts:

It looks like, according to the records here, that subscribers fell from about 190 million to 145 million over the past five years. Part of that is because Dish Network removed AT&T’s SportsNet and Root Sports channels earlier this month. In addition to that, a lot of consumers are moving towards streaming services to watch television, whether that be YouTubeTV, Amazon Prime or Hulu. We’re not getting those cable subscription channels that we once were. Part of that also is due to the pandemic over the past year and a half when fans weren’t allowed to go to the stadiums and sports networks had the bubbles, some consumers felt that it wasn’t the same experience, so they turned to other resources for entertainment.

 

Article written by Justin Honore.

More Like This Story:

Sport Radio Personality Colin Cowherd Launches Podcast Network

How Leigh Steinberg Created the Model for Modern Agents

How Sports Betting Took the U.S. by Storm

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More